This strategic approach allows for the rapid development of formulations that deliver bioequivalent doses of currently approved drugs, shortening the time to approval. The result is short timelines and significantly reduced capital requirements, enabling us to bring innovative treatments to patients more swiftly.

Our commitment to cutting-edge dry powder technology offers a superior alternative to outdated IM autoinjectors. By leveraging our knowledge of dry powder formulations, and utilizing the bioequivalence regulatory pathway, Nasdepi confirms our strategy and ability to accomplish our mission.

We are positioned to move a portfolio of products forward and collaborate with established pharmaceutical partners and government entities. Together, we aim to upgrade the delivery of existing drugs and make them accessible to patients worldwide, revolutionizing the standard of care for emergency medicines.